- Home
- BRN vs LPTX Comparison
BRN vs LPTX Comparison
Compare BRN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- LPTX
- Stock Information
- Founded
- BRN 1956
- LPTX 2011
- Country
- BRN United States
- LPTX United States
- Employees
- BRN N/A
- LPTX N/A
- Industry
- BRN Oil & Gas Production
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRN Energy
- LPTX Health Care
- Exchange
- BRN Nasdaq
- LPTX Nasdaq
- Market Cap
- BRN 13.0M
- LPTX 11.1M
- IPO Year
- BRN N/A
- LPTX N/A
- Fundamental
- Price
- BRN N/A
- LPTX $0.75
- Analyst Decision
- BRN
- LPTX Hold
- Analyst Count
- BRN 0
- LPTX 1
- Target Price
- BRN N/A
- LPTX N/A
- AVG Volume (30 Days)
- BRN 38.5K
- LPTX 7.6M
- Earning Date
- BRN 08-13-2025
- LPTX 11-12-2025
- Dividend Yield
- BRN N/A
- LPTX N/A
- EPS Growth
- BRN N/A
- LPTX N/A
- EPS
- BRN N/A
- LPTX N/A
- Revenue
- BRN $18,073,000.00
- LPTX N/A
- Revenue This Year
- BRN N/A
- LPTX N/A
- Revenue Next Year
- BRN N/A
- LPTX N/A
- P/E Ratio
- BRN N/A
- LPTX N/A
- Revenue Growth
- BRN N/A
- LPTX N/A
- 52 Week Low
- BRN $1.08
- LPTX $0.22
- 52 Week High
- BRN $2.32
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BRN 58.93
- LPTX 63.63
- Support Level
- BRN $1.17
- LPTX $0.46
- Resistance Level
- BRN $1.39
- LPTX $0.98
- Average True Range (ATR)
- BRN 0.09
- LPTX 0.11
- MACD
- BRN 0.01
- LPTX 0.03
- Stochastic Oscillator
- BRN 70.65
- LPTX 51.58
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.